No Detail Found!

Comparison of the Impact of SGLT2-Inhibitors and Exenatide on Body Fat Composition

Author(s)
Esma Agcakaya Department of Family Medicine, Faculty of Medicine, Istanbul Medeniyet University, Istanbul, Turkey
Hacer Hicran Mutlu Department of Family Medicine, Faculty of Medicine, Istanbul Medeniyet University, Istanbul, Turkey
Ayse Erbakan Division of Internal Medicine, Goztepe Prof Dr Suleyman Yalcin City Hospital, Istanbul, Turkey
Mehmet Sargin Department of Family Medicine, Faculty of Medicine, Istanbul Medeniyet University, Istanbul, Turkey
Abstract
Objective: To investigate the e ect of SGLT2-i and GLP-1RA as an add-on therapy to metformin on weight loss and body composition, and to compare their e ects on glucose and lipid parameters. Study Design: A descriptive study. Place and Duration of the Study: Goztepe Prof Dr Suleyman Yalcin City Hospital, from January 2016 to May 2021. Methodology: The study included 50 patients with diabetes on metformin+SGLT2-i (dapagli ozin or empagli ozin, group 1) and 50 patients with diabetes on metformin+GLP-1 receptor agonist (RA, exenatide, group 2). Results: The reduction in weight, BMI, total body, abdominal, leg, and arm fat percentage, and the improvement in body fat-free and muscle mass percentage were signi cantly higher in Group 2 (p<0.001, p<0.001, p=0.014; p=0.031, p<0.001; p=0.002 and p=0.014, p=0.014, respectively). The decline in abdominal fat mass in the GLP-1 RA group was also signi cant (p=0.031). There was a signi cant decrease in HbA1c, fasting glucose, and triglyceride levels (p<0.001, p<0.001, and p=0.036) with a signi cant increase in HDL-C (p=0.015). There was no signi cant di erence between groups for glucose, HbA1c, and lipid parameters (p>0.05). Conclusion: Both SGLT2 inhibitors and exenatide, when added to metformin therapy, were e ective in reducing weight and body fat, more by the GLP-agonist.SGLT2-i had no signi cant impact on decreasing abdominal fat depicting that these agents do not have any bene t in treating visceral adiposity.
Publication Details
Page(s) 308-313
Published Journal: Journal of College of Physicians and Surgeons--Pakistan : JCPSP, Volume: 33, Issue: 3, Year: 2023

Request the full text from PASTIC

Keywords
Type 2 diabetes mellitus, Obesity, Visceral adiposity., GLP-1 receptor, SGLT2 inhibitor, Body fat distribution
0

Citations

0

Downloads

50

Views